Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S. Flanigan SA, et al. Among authors: eckhardt sg. Clin Cancer Res. 2010 Nov 15;16(22):5436-46. doi: 10.1158/1078-0432.CCR-10-2054. Epub 2010 Oct 13. Clin Cancer Res. 2010. PMID: 20943761 Free PMC article.
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA Jr, Chan DC, Pallansch P, Eckhardt SG. Witta SE, et al. Among authors: eckhardt sg. Clin Cancer Res. 2004 Nov 1;10(21):7229-37. doi: 10.1158/1078-0432.CCR-03-0181. Clin Cancer Res. 2004. PMID: 15534096 Clinical Trial.
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, Herbst RS, Carducci M, Britten CD, Basche M, Eckhardt SG, Thornton D. Green LJ, et al. Among authors: eckhardt sg. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3408-15. doi: 10.1158/1078-0432.CCR-05-2231. Clin Cancer Res. 2006. PMID: 16740765
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG. Basche M, et al. Among authors: eckhardt sg. Clin Cancer Res. 2006 Sep 15;12(18):5471-80. doi: 10.1158/1078-0432.CCR-05-2423. Clin Cancer Res. 2006. PMID: 17000682 Clinical Trial.
Sunitinib: from rational design to clinical efficacy.
Chow LQ, Eckhardt SG. Chow LQ, et al. Among authors: eckhardt sg. J Clin Oncol. 2007 Mar 1;25(7):884-96. doi: 10.1200/JCO.2006.06.3602. J Clin Oncol. 2007. PMID: 17327610 Review.
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, Eckhardt SG. Troiani T, et al. Among authors: eckhardt sg. Clin Cancer Res. 2007 Nov 1;13(21):6450-8. doi: 10.1158/1078-0432.CCR-07-1094. Clin Cancer Res. 2007. PMID: 17975157
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. Adjei AA, et al. Among authors: eckhardt sg. J Clin Oncol. 2008 May 1;26(13):2139-46. doi: 10.1200/JCO.2007.14.4956. Epub 2008 Apr 7. J Clin Oncol. 2008. PMID: 18390968 Free PMC article. Clinical Trial.
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. O'Bryant CL, et al. Among authors: eckhardt sg. Cancer Chemother Pharmacol. 2009 Feb;63(3):477-89. doi: 10.1007/s00280-008-0761-3. Epub 2008 May 29. Cancer Chemother Pharmacol. 2009. PMID: 18509645 Free PMC article.
362 results